Evidence map›Paper›PMID 30531840›Full record

ArticleOncogene2019

CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development.

Yo-Taro Shirai, Anna Mizutani, Saori Nishijima, Masafumi Horie, Chisato Kikuguchi, Olga Elisseeva, Tadashi Yamamoto

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. ER-Localized DeadenylaseExploration (Beijing, China) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Gene regulatory Networks Reveal Sex Difference in Lung Adenocarcinoma.bioRxiv : the preprint server for biology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yo-Taro ShiraiCell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, Japan. yo-taro.shirai@nih.gov.
Anna MizutaniDivision of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Saori NishijimaCell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, Japan.
Masafumi HorieDepartment of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Chisato KikuguchiCell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, Japan.
Olga ElisseevaCell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, Japan.
Tadashi YamamotoCell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, Japan. tadashi.yamamoto@oist.jp.
Okinawa Institute of Science and Technology Graduate University · JPRIKEN Center for Integrative Medical Sciences · JPJapanese Foundation For Cancer Research · JPThe University of Tokyo · JP

Funding

MEXT | Japan Society for the Promotion of Science (JSPS) 16K18437MEXT | Japan Society for the Promotion of Science (JSPS) 21229006MEXT | Japan Society for the Promotion of Science (JSPS) 24890289MEXT | Japan Society for the Promotion of Science (JSPS) 25121734MEXT | Japan Society for the Promotion of Science (JSPS) 26830066MEXT | Japan Society for the Promotion of Science (JSPS) 26893050
6 · The paper itself

Abstract

Lung cancer is one of the major causes of cancer death and clarification of its molecular pathology is highly prioritized. The physiological importance of mRNA degradation through the CCR4-NOT deadenylase has recently been highlighted. For example, mutation in CNOT3, a gene coding for CNOT3 subunit of the CCR4-NOT complex, is found to be associated with T-cell acute lymphoblastic leukemia, T-ALL, though its contribution to other cancers has not been reported. Here, we provide evidence suggesting that CNOT3 is required for the growth of non-small cell lung cancer. Depletion of CNOT3 suppresses proliferation of A549 human non-small cell lung cancer cells with enhanced mRNA stability and subsequent elevated expression of p21. In addition, we identified the mRNA for Krüppel-like factor 2 transcription factor, an inducer of p21, as a novel mRNA degradation target of CNOT3 in non-small cell lung cancer cells. Aberrant up-regulation of Krüppel-like factor 2 by CNOT3 depletion leads to impairment in the proliferation of A549 cells. Consistent with these findings, elevated mRNA expression of CNOT3 in non-small cell lung cancer in comparison with the paired normal lung epithelium was confirmed through scrutinization of the RNA-sequencing datasets from The Cancer Genome Atlas. Moreover, we found an inverse correlation between CNOT3 and CDKN1A (encoding p21) mRNA expression using the combined datasets of normal lung epithelium and non-small cell lung cancer. Thus, we propose that the up-regulation of CNOT3 facilitates the development of non-small cell lung cancer through down-regulation of Krüppel-like factor 2 and p21, contrary to tumor suppressive functions of CNOT3 in T-ALL.

Indexed as

A549 CellsCarcinoma, Non-Small-Cell LungCell CycleCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21Down-RegulationGene Expression RegulationHumansKruppel-Like Transcription FactorsLung NeoplasmsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaRespiratory MucosaRNA, MessengerRNA StabilityTranscription FactorsCNOT3 protein, humanCyclin-Dependent Kinase Inhibitor p21Kruppel-Like Transcription FactorsRNA, MessengerTranscription Factors

Identifiers

PMID30531840
OpenAlexW2905084011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.